SG11201902884YA - Fused bicylic pyridine compounds and their use as ampa receptor modulators - Google Patents
Fused bicylic pyridine compounds and their use as ampa receptor modulatorsInfo
- Publication number
- SG11201902884YA SG11201902884YA SG11201902884YA SG11201902884YA SG11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA
- Authority
- SG
- Singapore
- Prior art keywords
- san diego
- california
- merryfield
- row
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412868P | 2016-10-26 | 2016-10-26 | |
| PCT/US2017/057566 WO2018080917A1 (en) | 2016-10-26 | 2017-10-20 | Fused bicylic pyridine compounds and their use as ampa receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201902884YA true SG11201902884YA (en) | 2019-05-30 |
Family
ID=60263053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201902884YA SG11201902884YA (en) | 2016-10-26 | 2017-10-20 | Fused bicylic pyridine compounds and their use as ampa receptor modulators |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10087185B2 (ko) |
| EP (1) | EP3532477B1 (ko) |
| JP (1) | JP6953527B2 (ko) |
| KR (1) | KR102416798B1 (ko) |
| CN (1) | CN109963851B (ko) |
| AU (1) | AU2017350689B2 (ko) |
| CA (1) | CA3039676A1 (ko) |
| CO (1) | CO2019004164A2 (ko) |
| EA (1) | EA036903B1 (ko) |
| IL (1) | IL266184B (ko) |
| MY (1) | MY192333A (ko) |
| SG (1) | SG11201902884YA (ko) |
| WO (1) | WO2018080917A1 (ko) |
| ZA (1) | ZA201903291B (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109890823B (zh) * | 2016-10-26 | 2021-11-30 | 詹森药业有限公司 | 稠合氮杂环化合物及其作为ampa受体调节剂的用途 |
| AU2020231118A1 (en) * | 2019-03-05 | 2021-10-28 | Centre For Addiction And Mental Health | Modulators of AMPA receptor signaling |
| US20220207386A1 (en) * | 2020-12-28 | 2022-06-30 | EMC IP Holding Company LLC | Best outcome aiops modeling with data confidence fabrics |
| CN112958154B (zh) * | 2021-03-07 | 2024-03-19 | 苏州大学 | 硅氨基稀土化合物在催化靛红化合物和环丙烯酮化合物反应中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001376A2 (en) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US20070293515A1 (en) * | 2004-08-03 | 2007-12-20 | Layton Mark E | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists |
| WO2008113795A1 (en) * | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP5498392B2 (ja) * | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0822425D0 (en) * | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
| NZ596053A (en) * | 2009-05-12 | 2013-05-31 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2011036889A1 (ja) * | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| CN109890823B (zh) * | 2016-10-26 | 2021-11-30 | 詹森药业有限公司 | 稠合氮杂环化合物及其作为ampa受体调节剂的用途 |
-
2017
- 2017-10-20 MY MYPI2019002331A patent/MY192333A/en unknown
- 2017-10-20 CA CA3039676A patent/CA3039676A1/en active Pending
- 2017-10-20 EA EA201991021A patent/EA036903B1/ru unknown
- 2017-10-20 EP EP17794524.3A patent/EP3532477B1/en active Active
- 2017-10-20 SG SG11201902884YA patent/SG11201902884YA/en unknown
- 2017-10-20 AU AU2017350689A patent/AU2017350689B2/en active Active
- 2017-10-20 CN CN201780066641.9A patent/CN109963851B/zh active Active
- 2017-10-20 JP JP2019522295A patent/JP6953527B2/ja active Active
- 2017-10-20 KR KR1020197014506A patent/KR102416798B1/ko active IP Right Grant
- 2017-10-20 WO PCT/US2017/057566 patent/WO2018080917A1/en unknown
- 2017-10-23 US US15/790,849 patent/US10087185B2/en active Active
-
2019
- 2019-04-23 IL IL266184A patent/IL266184B/en unknown
- 2019-04-26 CO CONC2019/0004164A patent/CO2019004164A2/es unknown
- 2019-05-24 ZA ZA2019/03291A patent/ZA201903291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109963851A (zh) | 2019-07-02 |
| KR20190067239A (ko) | 2019-06-14 |
| IL266184B (en) | 2021-10-31 |
| MY192333A (en) | 2022-08-17 |
| EP3532477B1 (en) | 2020-08-26 |
| IL266184A (en) | 2019-06-30 |
| EA036903B1 (ru) | 2021-01-13 |
| NZ751998A (en) | 2021-06-25 |
| ZA201903291B (en) | 2023-10-25 |
| CO2019004164A2 (es) | 2019-05-10 |
| CA3039676A1 (en) | 2018-05-03 |
| AU2017350689B2 (en) | 2021-05-20 |
| KR102416798B1 (ko) | 2022-07-04 |
| JP2019536760A (ja) | 2019-12-19 |
| WO2018080917A1 (en) | 2018-05-03 |
| CN109963851B (zh) | 2021-11-30 |
| US10087185B2 (en) | 2018-10-02 |
| EP3532477A1 (en) | 2019-09-04 |
| JP6953527B2 (ja) | 2021-10-27 |
| US20180111933A1 (en) | 2018-04-26 |
| AU2017350689A1 (en) | 2019-04-18 |
| EA201991021A1 (ru) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201902884YA (en) | Fused bicylic pyridine compounds and their use as ampa receptor modulators | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201908977SA (en) | Niraparib formulations | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408501UA (en) | Preparation, uses and solid forms of obeticholic acid | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201902873RA (en) | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201806401YA (en) | G protein-coupled receptor (gpcr) modulation by imipridones | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |